![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PGLS |
Gene summary for PGLS |
![]() |
Gene information | Species | Human | Gene symbol | PGLS | Gene ID | 25796 |
Gene name | 6-phosphogluconolactonase | |
Gene Alias | 6PGL | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | A0A0K0K1K7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25796 | PGLS | C43 | Human | Oral cavity | OSCC | 3.83e-25 | 7.25e-01 | 0.1704 |
25796 | PGLS | C46 | Human | Oral cavity | OSCC | 3.05e-53 | 1.43e+00 | 0.1673 |
25796 | PGLS | C51 | Human | Oral cavity | OSCC | 2.28e-31 | 1.65e+00 | 0.2674 |
25796 | PGLS | C57 | Human | Oral cavity | OSCC | 2.85e-40 | 1.39e+00 | 0.1679 |
25796 | PGLS | C06 | Human | Oral cavity | OSCC | 1.60e-10 | 1.93e+00 | 0.2699 |
25796 | PGLS | C07 | Human | Oral cavity | OSCC | 2.11e-06 | 1.56e+00 | 0.2491 |
25796 | PGLS | C08 | Human | Oral cavity | OSCC | 4.13e-88 | 1.95e+00 | 0.1919 |
25796 | PGLS | C09 | Human | Oral cavity | OSCC | 1.85e-14 | 7.76e-01 | 0.1431 |
25796 | PGLS | LN22 | Human | Oral cavity | OSCC | 6.32e-08 | 1.20e+00 | 0.1733 |
25796 | PGLS | LN38 | Human | Oral cavity | OSCC | 8.48e-14 | 2.00e+00 | 0.168 |
25796 | PGLS | LN46 | Human | Oral cavity | OSCC | 1.33e-21 | 1.11e+00 | 0.1666 |
25796 | PGLS | LP15 | Human | Oral cavity | LP | 3.53e-13 | 1.93e+00 | 0.2174 |
25796 | PGLS | LP17 | Human | Oral cavity | LP | 9.03e-08 | 1.12e+00 | 0.2349 |
25796 | PGLS | SYSMH1 | Human | Oral cavity | OSCC | 2.99e-26 | 9.36e-01 | 0.1127 |
25796 | PGLS | SYSMH2 | Human | Oral cavity | OSCC | 8.68e-41 | 1.79e+00 | 0.2326 |
25796 | PGLS | SYSMH3 | Human | Oral cavity | OSCC | 1.50e-49 | 1.97e+00 | 0.2442 |
25796 | PGLS | SYSMH4 | Human | Oral cavity | OSCC | 6.54e-12 | 5.59e-01 | 0.1226 |
25796 | PGLS | SYSMH5 | Human | Oral cavity | OSCC | 3.01e-21 | 8.77e-01 | 0.0647 |
25796 | PGLS | SYSMH6 | Human | Oral cavity | OSCC | 1.41e-25 | 9.15e-01 | 0.1275 |
25796 | PGLS | P4_S8_cSCC | Human | Skin | cSCC | 1.63e-09 | 2.36e-01 | -0.3095 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:000609114 | Cervix | HSIL_HPV | generation of precursor metabolites and energy | 32/737 | 490/18723 | 3.69e-03 | 3.27e-02 | 32 |
GO:000609124 | Cervix | N_HPV | generation of precursor metabolites and energy | 40/534 | 490/18723 | 2.59e-09 | 7.88e-07 | 40 |
GO:000609110 | Endometrium | AEH | generation of precursor metabolites and energy | 121/2100 | 490/18723 | 1.65e-17 | 8.23e-15 | 121 |
GO:000609115 | Endometrium | EEC | generation of precursor metabolites and energy | 125/2168 | 490/18723 | 3.76e-18 | 1.88e-15 | 125 |
GO:000609120 | Esophagus | HGIN | generation of precursor metabolites and energy | 145/2587 | 490/18723 | 3.41e-20 | 2.04e-17 | 145 |
GO:00060983 | Esophagus | HGIN | pentose-phosphate shunt | 7/2587 | 15/18723 | 2.22e-03 | 2.28e-02 | 7 |
GO:00067403 | Esophagus | HGIN | NADPH regeneration | 7/2587 | 16/18723 | 3.47e-03 | 3.22e-02 | 7 |
GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
GO:000674012 | Esophagus | ESCC | NADPH regeneration | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
GO:000609812 | Esophagus | ESCC | pentose-phosphate shunt | 12/8552 | 15/18723 | 7.31e-03 | 2.63e-02 | 12 |
GO:00067393 | Esophagus | ESCC | NADP metabolic process | 23/8552 | 35/18723 | 1.34e-02 | 4.38e-02 | 23 |
GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
GO:0006098 | Liver | Cirrhotic | pentose-phosphate shunt | 9/4634 | 15/18723 | 3.88e-03 | 2.10e-02 | 9 |
GO:0051156 | Liver | Cirrhotic | glucose 6-phosphate metabolic process | 12/4634 | 24/18723 | 6.58e-03 | 3.25e-02 | 12 |
GO:0006740 | Liver | Cirrhotic | NADPH regeneration | 9/4634 | 16/18723 | 6.94e-03 | 3.38e-02 | 9 |
GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
GO:00067401 | Liver | HCC | NADPH regeneration | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
GO:0006739 | Liver | HCC | NADP metabolic process | 25/7958 | 35/18723 | 5.05e-04 | 3.29e-03 | 25 |
GO:00060981 | Liver | HCC | pentose-phosphate shunt | 13/7958 | 15/18723 | 5.67e-04 | 3.61e-03 | 13 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0120016 | Esophagus | HGIN | Carbon metabolism | 31/1383 | 115/8465 | 2.51e-03 | 2.10e-02 | 1.67e-02 | 31 |
hsa0120017 | Esophagus | HGIN | Carbon metabolism | 31/1383 | 115/8465 | 2.51e-03 | 2.10e-02 | 1.67e-02 | 31 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa00030 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa000301 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa000302 | Liver | HCC | Pentose phosphate pathway | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0120051 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa000303 | Liver | HCC | Pentose phosphate pathway | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0120014 | Oral cavity | OSCC | Carbon metabolism | 74/3704 | 115/8465 | 6.10e-06 | 3.05e-05 | 1.55e-05 | 74 |
hsa0120015 | Oral cavity | OSCC | Carbon metabolism | 74/3704 | 115/8465 | 6.10e-06 | 3.05e-05 | 1.55e-05 | 74 |
hsa0120022 | Oral cavity | LP | Carbon metabolism | 62/2418 | 115/8465 | 8.38e-09 | 1.39e-07 | 8.99e-08 | 62 |
hsa0120032 | Oral cavity | LP | Carbon metabolism | 62/2418 | 115/8465 | 8.38e-09 | 1.39e-07 | 8.99e-08 | 62 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PGLS | SNV | Missense_Mutation | c.649N>C | p.Glu217Gln | p.E217Q | O95336 | protein_coding | tolerated(0.08) | benign(0.173) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PGLS | SNV | Missense_Mutation | rs376388573 | c.454N>A | p.Asp152Asn | p.D152N | O95336 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PGLS | SNV | Missense_Mutation | c.205N>T | p.Ser69Cys | p.S69C | O95336 | protein_coding | deleterious(0.05) | benign(0.332) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PGLS | SNV | Missense_Mutation | c.640C>T | p.Arg214Cys | p.R214C | O95336 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-EI-6511-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatinum+5-fu | SD | |
PGLS | SNV | Missense_Mutation | novel | c.457N>T | p.Gly153Cys | p.G153C | O95336 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PGLS | SNV | Missense_Mutation | novel | c.667N>T | p.Pro223Ser | p.P223S | O95336 | protein_coding | deleterious(0.03) | benign(0) | TCGA-B5-A5OD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
PGLS | SNV | Missense_Mutation | c.458N>A | p.Gly153Asp | p.G153D | O95336 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D1-A17F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PGLS | SNV | Missense_Mutation | rs146930299 | c.553N>T | p.Arg185Cys | p.R185C | O95336 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
PGLS | SNV | Missense_Mutation | novel | c.293N>G | p.His98Arg | p.H98R | O95336 | protein_coding | tolerated(0.18) | possibly_damaging(0.474) | TCGA-DD-AACE-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PGLS | deletion | Frame_Shift_Del | novel | c.445delG | p.Val149TrpfsTer38 | p.V149Wfs*38 | O95336 | protein_coding | TCGA-WQ-A9G7-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |